1. Home
  2. NGNE vs EVH Comparison

NGNE vs EVH Comparison

Compare NGNE & EVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$35.40

Market Cap

498.2M

Sector

Health Care

ML Signal

HOLD

Logo Evolent Health Inc

EVH

Evolent Health Inc

HOLD

Current Price

$5.58

Market Cap

469.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
EVH
Founded
2003
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
498.2M
469.0M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
NGNE
EVH
Price
$35.40
$5.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
15
Target Price
$63.57
$7.93
AVG Volume (30 Days)
219.9K
2.5M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
$907,957,000.00
Revenue This Year
N/A
$33.89
Revenue Next Year
N/A
$15.84
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.93
$2.10
52 Week High
$37.27
$11.81

Technical Indicators

Market Signals
Indicator
NGNE
EVH
Relative Strength Index (RSI) 68.81 65.82
Support Level $19.27 $3.67
Resistance Level $36.37 $8.30
Average True Range (ATR) 2.05 0.35
MACD 0.39 0.07
Stochastic Oscillator 95.22 80.50

Price Performance

Historical Comparison
NGNE
EVH

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.

Share on Social Networks: